Format

Send to

Choose Destination
J Cardiometab Syndr. 2009 Spring;4(2):113-9. doi: 10.1111/j.1559-4572.2008.00044.x.

The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: Part I. Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus.

Author information

1
Department of Medicine and the Irving Institute for Clinical and Translational Research, College of Physicians and Surgeons, Columbia University, New York, NY, USA. hng1@columbia.edu

Abstract

Both the metabolic syndrome (MS) and type 2 diabetes mellitus (T2DM) confer an increased risk of coronary heart disease and cardiovascular disease (CVD). As MS and T2DM become more prevalent, there will be an associated rise in the number of individuals with or at risk for CVD and its related disorders. One major underlying cause of CVD in patients with MS or T2DM is a characteristic form of atherogenic dyslipidemia. This article reviews the evidence that demonstrates that individuals with MS or T2DM are at increased risk for CVD and highlights atherogenic dyslipidemia as an important risk factor for the development of CVD in these individuals. In an accompanying article, current pharmacotherapies available for the management of atherogenic dyslipidemia in individuals with MS or T2DM are discussed.

PMID:
19614799
PMCID:
PMC2901596
DOI:
10.1111/j.1559-4572.2008.00044.x
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center